Intralymphatic Immunotherapy : Update and Unmet Needs
(2019) In International Archives of Allergy and Immunology 178(2). p.141-149- Abstract
Allergen-specific immunotherapy (AIT) is the only allergy treatment that confers long-term symptom amelioration for patients suffering from allergy. The most frequently used allergen application route is subcutaneous injection (SCIT), commonly taken as the gold standard, followed by sublingual (SLIT) or oral (OIT) application of allergen preparations. This is an up-to-date review of the clinical evidence for a novel route of allergen application, i.e., directly into lymph nodes - intralymphatic immunotherapy (ILIT). The major advantages of ILIT over the current AIT approaches are its short duration and the low allergen doses administered. The whole treatment consists of merely 3 ultrasound-guided injections into inguinal lymph nodes 1... (More)
Allergen-specific immunotherapy (AIT) is the only allergy treatment that confers long-term symptom amelioration for patients suffering from allergy. The most frequently used allergen application route is subcutaneous injection (SCIT), commonly taken as the gold standard, followed by sublingual (SLIT) or oral (OIT) application of allergen preparations. This is an up-to-date review of the clinical evidence for a novel route of allergen application, i.e., directly into lymph nodes - intralymphatic immunotherapy (ILIT). The major advantages of ILIT over the current AIT approaches are its short duration and the low allergen doses administered. The whole treatment consists of merely 3 ultrasound-guided injections into inguinal lymph nodes 1 month apart. While the number of patients included in randomised controlled trials is still limited, the clinical results for ILIT are encouraging, but more clinical trials are needed, as well as more preclinical work for optimising formulations.
(Less)
- author
- publishing date
- 2019
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- Allergen-specific immunotherapy, Allergy, Clinical trials, Intralymphatic immunotherapy
- in
- International Archives of Allergy and Immunology
- volume
- 178
- issue
- 2
- pages
- 141 - 149
- publisher
- Karger
- external identifiers
-
- scopus:85056460849
- pmid:30391954
- ISSN
- 1018-2438
- DOI
- 10.1159/000493647
- language
- English
- LU publication?
- no
- id
- 9c2f3c68-e627-405f-bf91-c442e777d040
- date added to LUP
- 2018-11-28 14:39:01
- date last changed
- 2024-04-15 17:42:48
@article{9c2f3c68-e627-405f-bf91-c442e777d040, abstract = {{<p>Allergen-specific immunotherapy (AIT) is the only allergy treatment that confers long-term symptom amelioration for patients suffering from allergy. The most frequently used allergen application route is subcutaneous injection (SCIT), commonly taken as the gold standard, followed by sublingual (SLIT) or oral (OIT) application of allergen preparations. This is an up-to-date review of the clinical evidence for a novel route of allergen application, i.e., directly into lymph nodes - intralymphatic immunotherapy (ILIT). The major advantages of ILIT over the current AIT approaches are its short duration and the low allergen doses administered. The whole treatment consists of merely 3 ultrasound-guided injections into inguinal lymph nodes 1 month apart. While the number of patients included in randomised controlled trials is still limited, the clinical results for ILIT are encouraging, but more clinical trials are needed, as well as more preclinical work for optimising formulations.</p>}}, author = {{Senti, Gabriela and Freiburghaus, Andreas U. and Larenas-Linnemann, Désirée and Hoffmann, Hans Jürgen and Patterson, Amber M. and Klimek, Ludger and Di Bona, Danilo and Pfaar, Oliver and Ahlbeck, Lars and Akdis, Mübeccel and Weinfeld, Dan and Contreras-Verduzco, Francisco A. and Pedroza-Melendez, Alvaro and Skaarup, Søren H. and Lee, Sang Min and Cardell, Lars Olaf and Schmid, Johannes M. and Westin, Ulla and Dollner, Ralph and Kündig, Thomas M.}}, issn = {{1018-2438}}, keywords = {{Allergen-specific immunotherapy; Allergy; Clinical trials; Intralymphatic immunotherapy}}, language = {{eng}}, number = {{2}}, pages = {{141--149}}, publisher = {{Karger}}, series = {{International Archives of Allergy and Immunology}}, title = {{Intralymphatic Immunotherapy : Update and Unmet Needs}}, url = {{http://dx.doi.org/10.1159/000493647}}, doi = {{10.1159/000493647}}, volume = {{178}}, year = {{2019}}, }